Compare ECOR & SWZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECOR | SWZ |
|---|---|---|
| Founded | 2005 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 76.6M |
| IPO Year | 2018 | N/A |
| Metric | ECOR | SWZ |
|---|---|---|
| Price | $5.00 | $6.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $25.50 | N/A |
| AVG Volume (30 Days) | ★ 41.6K | 14.2K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.59% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,835,000.00 | N/A |
| Revenue This Year | $28.61 | N/A |
| Revenue Next Year | $41.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.90 | N/A |
| 52 Week Low | $4.16 | $7.12 |
| 52 Week High | $19.49 | $8.57 |
| Indicator | ECOR | SWZ |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 58.19 |
| Support Level | $4.42 | $6.20 |
| Resistance Level | $4.96 | $6.25 |
| Average True Range (ATR) | 0.32 | 0.05 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 100.00 | 55.63 |
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, Semiconductors, Information Technology, and retail.